Guidance and quality standards Awaiting development

Skip to filtersSkip to results

Skip to results

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 151 to 200 of 284

TitleType
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Technology appraisal guidance
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia ID6347Technology appraisal guidance
Obinutuzumab for treating lupus nephritis TID6420Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Technology appraisal guidance
Omaveloxolone for treating Friedreich's ataxia in people aged 16 to 40 TS ID 11922Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]Technology appraisal guidance
Ondansetron for treating alcohol-use disorder TS ID 11884Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941Technology appraisal guidance
Oral semaglutide for managing overweight and obesity [ID6188]Technology appraisal guidance
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]Technology appraisal guidance
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID 6399Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer TS ID 11852Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID4065]Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Technology appraisal guidance
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810Technology appraisal guidance
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]Technology appraisal guidance
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975Technology appraisal guidance
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer [ID6381]Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Technology appraisal guidance
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines TS ID 11903Technology appraisal guidance
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer TS ID 11851Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All